Abstract:The American Academy of Pediatrics and the Canadian Paediatric Society both advise that all newborns should undergo bilirubin screening before leaving the hospital, and this has become the standard practice in both countries. However, the US Preventive Task Force has found no strong evidence to suggest that this practice of universal screening for bilirubin reduces the occurrence of significant outcomes such as bilirubin‐induced neurologic dysfunction or kernicterus. To evaluate the effectiveness of transcutaneous screening compared to visual inspection for hyperbilirubinemia to prevent the readmission of newborns (infants greater than 35 weeks' gestation) for phototherapy. We searched CENTRAL, MEDLINE, Embase, CINAHL, ClinicalTrials.gov, ICTRP, and ISRCTN in June 2023. We also searched conference proceedings, and the reference lists of included studies. We included randomized controlled trials (RCTs), quasi‐randomized, cluster‐randomized, or prospective cohort studies with control arm that evaluated the use of transcutaneous bilirubin (TcB) screening for hyperbilirubinemia in newborns before hospital discharge. We used standard methodologic procedures expected by Cochrane. We evaluated treatment effects using a fixed‐effect model with risk ratio (RR) and 95% confidence intervals (CI) for categorical data and mean, standard deviation (SD), and mean difference (MD) for continuous data. We used the GRADE approach to evaluate the certainty of evidence. We identified one RCT (1858 participants) that met our inclusion criteria. The study included 1858 African newborns at 35 weeks' gestation or greater who were receiving routine care at a well‐baby nursery, and were randomly recruited prior to discharge to undergo TcB screening. The study had good methodologic quality. TcB screening versus visual assessment of hyperbilirubinemia in newborns: – may reduce readmission to the hospital for hyperbilirubinemia (RR 0.25, 95% CI 0.14 to 0.46; P < 0.0001; moderate‐certainty evidence); – probably has little or no effect on the rate of exchange transfusion (RR 0.20, 95% CI 0.01 to 14.16; low‐certainty evidence); – may increase the number of newborns who require phototherapy prior to discharge (RR 2.67, 95% CI 1.56 to 4.55; moderate‐certainty evidence). – probably has little or no effect on the rate of acute bilirubin encephalopathy (RR 0.33, 95% CI 0.01 to 8.18; low‐certainty evidence). The study did not evaluate or report cost of care. Moderate‐certainty evidence suggests that TcB screening may reduce readmission for hyperbilirubinemia compared to visual inspection. Low‐certainty evidence also suggests that TcB screening probably has little or no effect on the rate of exchange transfusion compared to visual inspection. However, moderate‐certainty evidence suggests that TcB screening may increase the number of newborns that require phototherapy before discharge compared to visual inspection. Low‐certainty evidence suggests that TcB screening probably has little or no effect on the rate of acute bilirubin encephalopathy compared to visual inspection. Given that we have only identified one RCT, further studies are necessary to determine whether TcB screening can help to reduce readmission and complications related to neonatal hyperbilirubinemia. In settings with limited newborn follow‐up after hospital discharge, identifying newborns at risk of severe hyperbilirubinemia before hospital discharge will be important to plan targeted follow‐up of these infants. Key messages – Jaundice is a common newborn condition. If left undetected and untreated, it can lead to brain injury. – Screening newborn babies by measuring jaundice levels through the skin (called transcutaneous bilirubin screening) may lead to a reduction in readmission for light therapy. It does lead to more babies having light therapy before discharge from the hospital and has little or no effect on the number of babies who require an exchange blood transfusion to treat their jaundice. It has little or no effect on the number of babies that have early brain injury. – Further studies are needed that investigate the effect of transcutaneous bilirubin screening on newborns prior to discharge. What is jaundice? Jaundice refers to yellowish discoloration of the skin and the white of the eyes. It occurs because of an increase in a pigment in the blood called bilirubin. When bilirubin levels in the blood increase, it gets deposited in the skin and eyes, and causes them to become yellow. Jaundice is a very common condition in newborns. In most cases, the condition is harmless and does not require any treatment. However, in some instances, the newborn requires treatment in the form of phototherapy (light therapy) or exchange blood transfusion (where some of the newborn's blood is removed and replaced with donor blood). Very high levels of bilirubin in the blood (called hyperbilirubinemia) can c -Abstract Truncated-

Non-invasive detection of bilirubin concentrations during the first week of life in a low-resource setting along the Thailand-Myanmar border

Evaluation of the Bilichek Transcutaneous Bilirubinometer in the Chinese New-Borns

[Evaluation of an Automatic Image-Based Screening Technique for Neonatal Hyperbilirubinemia].

Neonatal hyperbilirubinemia management: Clinical assessment of bilirubin production.

[Predictive Value of Umbilical Cord Blood Bilirubin Level for Subsequent Neonatal Jaundice].

Total serum bilirubin levels during the first 2 days of life and subsequent neonatal morbidity in very low birth weight infants: a retrospective review

An End-Tidal Carbon Monoxide Nomogram for Term and Late-Preterm Chinese Newborns.

Neonatal Bilirubin Binding Capacity Discerns Risk of Neurological Dysfunction

Analytical Performance Validation and Clinical Application of Blood Gas Analyzer on the Detection of Neonatal Bilirubin

Utility of Jaundice Surveillance and Bilirubin Screening in Identifying Neonates Who Qualify for Phototherapy ≤ 24 Hours After Birth

Parental Detection of Neonatal Jaundice Using a Low-Cost Colour Card: a Multicentre Prospective Study.

Use of a Smartphone App to Assess Neonatal Jaundice

Validity of BiliDx as a point-of-care bilirubin measurement device to diagnose and monitor neonatal jaundice at Muhimbili National Hospital, an observational study

Accuracy and Reliability of Whole Blood Bilirubin Measurements Using a Roche Blood Gas Analyzer for Neonatal Hyperbilirubinemia Screening and Risk Stratification

A Method for Compensating Hemoglobin Interference in Total Serum Bilirubin Measurement Using a Simple Two-Wavelength Reflectance Photometer

Issues for standardization of neonatal bilirubinemia: a case of delayed phototherapy initiation

Cord blood bilirubin and prediction of neonatal hyperbilirubinemia and perinatal infection in newborns at risk of hemolysis

Machine Learning to Improve Accuracy of Transcutaneous Bilirubinometry

Application of machine learning algorithms for accurate determination of bilirubin level on in vitro engineered tissue phantom images

Bilirubin measurements in neonates: uniform neonatal treatment can only be achieved by improved standardization

Transcutaneous bilirubinometry for detecting jaundice in term or late preterm neonates